What is the clinical impact of hyperkalaemia?

25 May 2019 (13:35 - 13:45)

Organised by:

About the speaker

Professor Cecilia Marianne Linde

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail

Chair's introduction - The hyperkalaemia challenge in heart failure: what is the role of novel agents?

Professor A. Stewart Coats (Sydney, AU)

Presentation thumbnail

Hyperkalaemia: a barrier to optimal management of patients with heart failure?

Professor A. Stewart Coats (Sydney, AU)

Presentation thumbnail

Solving the K+ challenge in heart failure: are novel K+ binders the answer?

Professor M. Volterrani (Rome, IT)

Presentation thumbnail

Clinical experience with novel K+ binders: what are the opportunities and challenges?

Professor C. Linde (Stockholm, SE) Professor A. Stewart Coats (Sydney, AU) Professor M. Volterrani (Rome, IT)

Access the full session

Session thumbnail

The hyperkalaemia challenge in heart failure: what is the role of novel agents?

The Event

Heart Failure 2019

25 May 2019 13:35 CET

You may be interested in

Congress Presentation

Challenges of managing hyperkalaemia in HF patients with CKD while maintaining RAAS inhibitor therapy

31 August 2024

Webinar

ACVC Biomarker Talk Series - How to implement novel diagnostic algorithms in the emergency room

19 January 2022

Congress Presentation

What is the treatment and management for patients with hypokalaemia? A critical review of the literature

13 June 2025

Congress Presentation

Effects of hyperkalaemia and worsening renal function on pharmacotherapy in hospitalized patients with heart failure

20 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources